Recently Viewed
Clear All$8.03
$0.18
(2.29%)
As on 02-Apr-2026 19:45EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$196 Mln
Revenue (TTM)
$74 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
-25.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$7.9
EPS
$-2.4
Face value
--
Shares outstanding
28,423,069
CFO
$-257.39 Mln
EBITDA
$-396.19 Mln
Net Profit
$-433.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
| 31.0 | -2.4 | 31.0 | -14.8 | -30.5 | -27.6 | -11.6 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
| -63.9 | -45.9 | 85.9 | -54.2 | -14.7 | 299.1 | 140.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings (ARCT)
|
8.0 | 196.1 | 67.2 | -65.8 | -100.8 | -28.9 | -- | 0.9 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a... lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Address: 10285 Science Center Drive, San Diego, CA, United States, 92121 Read more
Founder, President, CEO & Director
Mr. Joseph E. Payne M.Sc.
Founder, President, CEO & Director
Mr. Joseph E. Payne M.Sc.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arcturus Therapeutics Holdings Inc (ARCT) is $8.03 (NASDAQ) as of 02-Apr-2026 19:45 EDT. Arcturus Therapeutics Holdings Inc (ARCT) has given a return of -30.55% in the last 3 years.
Since, TTM earnings of Arcturus Therapeutics Holdings Inc (ARCT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.52
|
0.77
|
|
2024
|
-5.66
|
1.90
|
|
2023
|
-28.64
|
3.06
|
|
2022
|
48.98
|
1.69
|
|
2021
|
-4.72
|
4.22
|
The 52-week high and low of Arcturus Therapeutics Holdings Inc (ARCT) are Rs 24.17 and Rs 5.85 as of 05-Apr-2026.
Arcturus Therapeutics Holdings Inc (ARCT) has a market capitalisation of $ 196 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arcturus Therapeutics Holdings Inc (ARCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.